Pharmaceutical companies and public health advocates worldwide are keeping an eye on a legal case in India, in which pharmaceutical giant Bayer is appealing a decision by the Indian patent controller to override the company’s monopoly on its cancer drug Nexavar.
If upheld, the decision will allow an Indian company to produce and sell the drug for the equivalent of $173 U.S. dollars a month, the Financial Times reports.
Bayer’s pricing would ...
continue reading...